Genmab — Maj 2021
-
-
Conclusion
Talquetamab, at the RP2D of weekly 405 μg/kg SC, demonstrated a high clinical response rate and was well-tolerated in patients with relapsed/refractory MM. Based on the pharmacokinetic data, other SC dosing strategies are also being explored. The promising efficacy and safety profile, and the convenience of SC dosing support monotherapy development and combination approaches with this novel agent.
-
11:39 agree E L, for me epco also looks best-in-class
-
we still to have wait to see if Glofi comes with a subcu version, but if not epco clearly looks like a potential winner
-
God morgen
-
God morgen.
-
Spørgsmål til Q&A er meget velkommen.
-
Udover Q&A mandag har Proinvestor
sammen med Nordnet biotekwebinar med Genmab, Bavarian og Zealand Pharma tirsdag. Tlmelding: https://events.nordnet.dk/nordnet-events/kom-helt-taet-paa-tre-biotekvirksomheder-bavarian-zealand-pharma-genmab/ -
Er det ikke en meget meget lille short interest pt?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind